NR0B2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07590(NR0B2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P07590(NR0B2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The nuclear receptor subfamily 0 group B member 2 (NR0B2), also known as Small Heterodimer Partner (SHP), is an atypical orphan nuclear receptor lacking a DNA-binding domain. It functions as a transcriptional regulator by interacting with other nuclear receptors (e.g., LRH-1. FXR, HNF4α) and repressing their activity. NR0B2 plays a critical role in metabolic pathways, including bile acid synthesis, cholesterol homeostasis, glucose metabolism, and hepatic lipogenesis. Its dysregulation is associated with metabolic disorders, liver diseases, and cancer.

NR0B2 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore NR0B2's regulatory mechanisms in tissues, particularly the liver and intestines. Researchers also employ these antibodies to investigate its role in diseases such as non-alcoholic fatty liver disease (NAFLD), diabetes, and obesity.

Commercially available NR0B2 antibodies are typically raised against specific epitopes of human or mouse NR0B2 proteins. Validation includes reactivity checks across species, specificity confirmation via knockout controls, and application-specific performance testing. These antibodies support both basic research and therapeutic development, as NR0B2 is considered a potential drug target for metabolic syndrome and cholestatic liver disorders.